ANNOVIS BIO (ANVS) Fundamental Analysis & Valuation

NYSE:ANVS • US03615A1088

Current stock price

2.385 USD
-0.12 (-4.6%)
Last:

This ANVS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ANVS Profitability Analysis

1.1 Basic Checks

  • ANVS had negative earnings in the past year.
  • ANVS had a negative operating cash flow in the past year.
  • In the past 5 years ANVS always reported negative net income.
  • ANVS had a negative operating cash flow in each of the past 5 years.
ANVS Yearly Net Income VS EBIT VS OCF VS FCFANVS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M -50M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -136.87%, ANVS is doing worse than 82.47% of the companies in the same industry.
  • ANVS's Return On Equity of -171.23% is on the low side compared to the rest of the industry. ANVS is outperformed by 67.05% of its industry peers.
Industry RankSector Rank
ROA -136.87%
ROE -171.23%
ROIC N/A
ROA(3y)-288.01%
ROA(5y)-193.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ANVS Yearly ROA, ROE, ROICANVS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 -1K

1.3 Margins

  • ANVS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANVS Yearly Profit, Operating, Gross MarginsANVS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. ANVS Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, ANVS has more shares outstanding
  • The number of shares outstanding for ANVS has been increased compared to 5 years ago.
  • There is no outstanding debt for ANVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ANVS Yearly Shares OutstandingANVS Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
ANVS Yearly Total Debt VS Total AssetsANVS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

2.2 Solvency

  • ANVS has an Altman-Z score of -4.47. This is a bad value and indicates that ANVS is not financially healthy and even has some risk of bankruptcy.
  • ANVS has a Altman-Z score of -4.47. This is in the lower half of the industry: ANVS underperforms 61.08% of its industry peers.
  • There is no outstanding debt for ANVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.47
ROIC/WACCN/A
WACCN/A
ANVS Yearly LT Debt VS Equity VS FCFANVS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 5.80 indicates that ANVS has no problem at all paying its short term obligations.
  • ANVS has a Current ratio of 5.80. This is in the better half of the industry: ANVS outperforms 61.27% of its industry peers.
  • ANVS has a Quick Ratio of 5.80. This indicates that ANVS is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 5.80, ANVS is in the better half of the industry, outperforming 62.04% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.8
Quick Ratio 5.8
ANVS Yearly Current Assets VS Current LiabilitesANVS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ANVS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 23.08% over the past year.
EPS 1Y (TTM)23.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.3%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 25.28% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-1.82%
EPS Next 2Y4.37%
EPS Next 3Y-14.68%
EPS Next 5Y25.28%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANVS Yearly Revenue VS EstimatesANVS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
ANVS Yearly EPS VS EstimatesANVS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4 6 -6

More info and screens

Find the best growth stocksShow best growing peers

0

4. ANVS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ANVS. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANVS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANVS Price Earnings VS Forward Price EarningsANVS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANVS Per share dataANVS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

  • ANVS's earnings are expected to decrease with -14.68% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.37%
EPS Next 3Y-14.68%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ANVS Dividend Analysis

5.1 Amount

  • No dividends for ANVS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ANVS Fundamentals: All Metrics, Ratios and Statistics

ANNOVIS BIO

NYSE:ANVS (3/24/2026, 2:32:02 PM)

2.385

-0.12 (-4.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-13
Earnings (Next)05-11
Inst Owners20.17%
Inst Owner Change70.81%
Ins Owners15.41%
Ins Owner Change3.94%
Market Cap67.64M
Revenue(TTM)N/A
Net Income(TTM)-28.85M
Analysts82
Price Target14.03 (488.26%)
Short Float %12.25%
Short Ratio6.5
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-15.15%
Min EPS beat(2)-18.93%
Max EPS beat(2)-11.37%
EPS beat(4)2
Avg EPS beat(4)0.93%
Min EPS beat(4)-18.93%
Max EPS beat(4)22.06%
EPS beat(8)4
Avg EPS beat(8)4.16%
EPS beat(12)5
Avg EPS beat(12)-26.9%
EPS beat(16)7
Avg EPS beat(16)-20.78%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.01
P/tB 4.01
EV/EBITDA N/A
EPS(TTM)-1.4
EYN/A
EPS(NY)-1.43
Fwd EYN/A
FCF(TTM)-0.9
FCFYN/A
OCF(TTM)-0.9
OCFYN/A
SpS0
BVpS0.59
TBVpS0.59
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -136.87%
ROE -171.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-288.01%
ROA(5y)-193.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.8
Quick Ratio 5.8
Altman-Z -4.47
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.3%
EPS Next Y-1.82%
EPS Next 2Y4.37%
EPS Next 3Y-14.68%
EPS Next 5Y25.28%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-11.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-55.34%
EBIT Next 3Y-80.63%
EBIT Next 5Y45.47%
FCF growth 1Y-17.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.01%
OCF growth 3YN/A
OCF growth 5YN/A

ANNOVIS BIO / ANVS Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ANNOVIS BIO?

ChartMill assigns a fundamental rating of 2 / 10 to ANVS.


What is the valuation status of ANNOVIS BIO (ANVS) stock?

ChartMill assigns a valuation rating of 0 / 10 to ANNOVIS BIO (ANVS). This can be considered as Overvalued.


What is the profitability of ANVS stock?

ANNOVIS BIO (ANVS) has a profitability rating of 0 / 10.


What is the earnings growth outlook for ANNOVIS BIO?

The Earnings per Share (EPS) of ANNOVIS BIO (ANVS) is expected to decline by -1.82% in the next year.